Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2026 | Mkt Perform | William Blair | |
| 7/15/2025 | $9.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/10/2025 | $9.00 | Buy → Hold | Jefferies |
| 7/9/2025 | Outperform → Perform | Oppenheimer | |
| 7/9/2025 | $9.00 | Overweight → Equal Weight | Wells Fargo |
| 7/9/2025 | Buy → Neutral | BTIG Research | |
| 5/19/2025 | $25.00 | Equal Weight → Overweight | Wells Fargo |
| 4/15/2025 | $18.00 | Neutral | Piper Sandler |
William Blair initiated coverage of RxSight with a rating of Mkt Perform
Morgan Stanley downgraded RxSight from Overweight to Equal-Weight and set a new price target of $9.00
Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LA
ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 unitsRobust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustabilityRecent regulatory approval in New Zealand furthering the company's international footprint and global market opportunity2026 sales and gross margin guidance u
ALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, col
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
10-Q - RxSight, Inc. (0001111485) (Filer)
8-K - RxSight, Inc. (0001111485) (Filer)
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig
ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 unitsRobust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustabilityRecent regulatory approval in New Zealand furthering the company's international footprint and global market opportunity2026 sales and gross margin guidance u
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link s
ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growthRxSight's FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from conte
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)